Seth S. Martin, MD, MHS, FACC, FAHA, FASPC

Associate Professor
Johns Hopkins
Reisterstown, Maryland, United States

Dr. Martin is a preventive cardiologist at Johns Hopkins Hospital. He is a core faculty member in the Ciccarone Center for the Prevention of Cardiovascular Disease, where he directs the advanced lipid disorders program and health technology innovation. A dedicated clinician and clinical educator, Dr. Martin is a member of the Hopkins Bedside Medicine Faculty. He serves as a Firm Faculty Clinical Coach and Educator in the Osler Medical Residency. Dr. Martin has published more than 200 articles in leading cardiology and medicine journals, as well as 15 book chapters. Dr. Martin led the development of a more accurate system for estimating LDL cholesterol. Dr. Martin was selected as one of 125 individuals who personify Johns Hopkins Medicine’s mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care.

Presentation(s):

• State of the Art in LDL-C Assessment & Management: How Low Can We Go?

  Saturday, February 25, 2023
  4:22 PM – 4:30 PM ET

  Disclosure(s): Amgen, Sanofi/Regeneron, Esperion, Novo Nordisk, Akcea: Scientific Advisory Board (Ongoing); Novartis Pharmaceuticals: Scientific Advisory Board (Ongoing)

• Digital Health in Preventive Cardiology

  Saturday, February 25, 2023
  5:10 PM – 5:18 PM ET

  Disclosure(s): Amgen, Sanofi/Regeneron, Esperion, Novo Nordisk, Akcea: Scientific Advisory Board (Ongoing); Novartis Pharmaceuticals: Scientific Advisory Board (Ongoing)

• Panel Discussion: Atherosclerosis Therapeutic Options and Management

  Saturday, February 25, 2023
  5:26 PM – 5:35 PM ET

  Disclosure(s): Amgen, Sanofi/Regeneron, Esperion, Novo Nordisk, Akcea: Scientific Advisory Board (Ongoing); Novartis Pharmaceuticals: Scientific Advisory Board (Ongoing)

• Leveling the Playing Field: Can AI and Digital Health Reduce Healthcare Disparities? Digital Health Technology in Cardiovascular Disease

  Sunday, February 26, 2023
  8:46 PM – 8:54 PM ET

  Disclosure(s): Amgen, Sanofi/Regeneron, Esperion, Novo Nordisk, Akcea: Scientific Advisory Board (Ongoing); Novartis Pharmaceuticals: Scientific Advisory Board (Ongoing)

• Panel Discussion How to Close the Gap of Disparity in Clinical Trials and Beyond

  Sunday, February 26, 2023
  8:54 PM – 9:05 PM ET

  Disclosure(s): Amgen, Sanofi/Regeneron, Esperion, Novo Nordisk, Akcea: Scientific Advisory Board (Ongoing); Novartis Pharmaceuticals: Scientific Advisory Board (Ongoing)